EBS News and Press, Emergent Biosolutions Inc. From 02/21/24

Emergent BioSolutions Inc. (NYSE: EBS) is one today's most active stocks by volume. So far today, approximately 47.84M shares of Emergent BioSolutions Inc. have been exchanged, as compared to an average 30-day volume of 1.56M shares. Emergent BioSolutions Inc., a life sciences company, focuses...

2024-02-21 08:04:03 ET DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Emergent BioSolutions Inc. (NYSE: EBS ) reported, this morning, that Joseph C. Papa was appointed president and CEO, effective today. EBS is trading at $1.71, up $0.19 (+12.50%), on 46K shares traded. It...

2024-02-21 07:13:49 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow Emergent BioSolutions extends shelf life of Narcan to 4 years Emergent BioSolutions win...

Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address pu...

2024-01-22 05:00:00 ET Summary After a correction from August through October, the market has been on a tear. Technology had a very good week, especially among the Magnificent 7 mega-cap stocks. The S&P Top 7 stocks continue to dominate the market, but that dominance is sl...

2024-01-17 14:46:11 ET More on Emergent BioSolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow Emergent BioSolutions Inc. 2023 Q3 - Results - Earnings Call Presentation Emergent BioS...

2024-01-11 08:18:58 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow Emergent BioSolutions Inc. 2023 Q3 - Results - Earnings Call Presentation Emergent Bios...

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax ® (Anthrax Vaccine Adsorbed)...

GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich L...

2023-12-18 02:51:34 ET Summary Emergent BioSolutions stock has a call option-like structure to it and trades as an equity stub currently behind a high debt load. However, business performance may be improving into the important Q4 period, with results coming in February 2024. ...